The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer

The Institute of Cancer Research, London, has expressed disappointment that the prostate cancer drug abiraterone (brand name Zytiga) will not be made available to men with advanced prostate cancer as a first-line treatment on the NHS.
Institute of Cancer Research